Loading...

Purified anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_Purified_041106
C57BL/6 mouse splenocytes were stained with purified CD8 (clone 53-6.7) (filled histogram) or rat IgG2a, κ isotype control (open histogram), followed by anti-rat IgG FITC.
  • 53-6dot7_Purified_041106
    C57BL/6 mouse splenocytes were stained with purified CD8 (clone 53-6.7) (filled histogram) or rat IgG2a, κ isotype control (open histogram), followed by anti-rat IgG FITC.
  • 53-6dot7_Purified_IHC_011917
    C57BL/6 frozen mouse spleen section was fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS for 30 minutes at room temperature. Then the section was stained with 10 µg/mL of purified anti-mouse CD8a (clone 53-6.7), 10 µg/mL of Alexa Fluor® 647 anti-CD20 (green) overnight at 4°C, followed by 2.5 µg/mL of Alexa Fluor® 594 anti-rat IgG2a (clone MRG2a-83) (red) for two hours at room temperature. The image was captured by 10X objective.
  • 53-6dot7_Purified_IHC_102418
    Fresh, frozen mouse spleen was stained with purified CD8a clone 53-6.7 conjugated and detected with a Cy3 CODEX™ oligonucleotide duplex (red). Samples were counterstained with B220 FITC (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
Compare all formats
Cat # Size Price Save
100701 50 µg ¥6,410
100702 500 µg ¥23,540
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/mL
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF®, IHC-F - Verified
IP - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µL volume. For immunohistochemistry on frozen tissue sections, the suggested use of this reagent is 5.0 - 10 µg per mL. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Dallari S, et al. 2017. Nat Commun. 8:14830. PubMed
  2. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  3. Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed
  4. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
  5. Tersteegen A, et al. 2021. Infect Immun. 89:. PubMed
  6. Kao C, et al. 2005. Int Immunol. 1.824305556. PubMed
  7. Krovi SH, et al. 2019. Proc Natl Acad Sci U S A. 116:22252. PubMed
  8. Thelin MA, et al. 2017. Diabetes. 66:2220. PubMed
  9. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
  10. Asthagiri Arunkumar G, et al. 2019. Vaccine. 37:5567. PubMed
  11. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  12. Chartrand K, et al. 2018. Front Immunol. 1.642361111. PubMed
  13. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  14. Murata A, et al. 2020. Front Immunol. 11:775. PubMed
  15. Wang C, et al. 2020. Oncoimmunology. 9:1809947. PubMed
  16. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  17. Rubio‐Patiño C et al. 2018. Cell metabolism. 27(4):828-842 . PubMed
  18. Rieck M, et al. 2017. Eur J Immunol. 47:677. PubMed
  19. Goel S, et al. 2017. Nature. 548:471. PubMed
  20. Bradford BM, et al. 2018. Parasite Immunol. 40:e12566. PubMed
  21. Field CS, et al. 2018. Oncoimmunology. 7:e1376154. PubMed
  22. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  23. Boldison J, et al. 2020. Cell Mol Immunol. 17:843. PubMed
  24. Prado C, et al. 2021. J Neuroinflammation. 18:292. PubMed
  25. Carpenter SM, et al. 2017. PLoS Pathog. 13:e1006704. PubMed
  26. Gao J, et al. 2017. Oncol Lett. 14:2954. PubMed
  27. Haque M, et al. 2021. Viruses. 13:. PubMed
  28. Mayer JU, et al. 2020. Front Immunol. 11:592325. PubMed
  29. Tian K, et al. 2021. J Immunol Res. 2021:6297332. PubMed
  30. Nguyen N, et al. 2022. iScience. 25:103679. PubMed
  31. Hirano J, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  32. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
  33. Rossi DC, et al. 2021. J Clin Invest. 131:. PubMed
  34. Zhou AC, et al. 2017. Front Immunol. 1.136111111. PubMed
  35. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  36. Kaplanov I, et al. 2019. Proc Natl Acad Sci U S A. 116:1361. PubMed
  37. Niss Arfelt K, et al. 2017. Blood. 129:866. PubMed
  38. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  39. Willimsky G, et al. 2021. Elife. 10:. PubMed
  40. Tian D, et al. 2020. FASEB J. 34:3367. PubMed
  41. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  42. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
  43. Bartsch YC, et al. 2018. Front Immunol. 1.196527778. PubMed
  44. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  45. Recino A, et al. 2019. Gene Ther. 26:40. PubMed
  46. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  47. Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed
  48. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  49. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
  50. Hiramatsu-Asano S, et al. 2021. Front Immunol. 11:616141. PubMed
  51. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  52. Sun H, et al. 2018. J Cell Biol. 217:1453. PubMed
  53. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
  54. Guo Y, et al. 2008. Blood. 112:480. PubMed
  55. Wang N, et al. 2021. Mol Ther Oncolytics. 20:71. PubMed
  56. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  57. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  58. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  59. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  60. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  61. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  62. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  63. Hiratsuka S, et al. 2018. EMBO Mol Med. 10:e8643. PubMed
  64. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  65. Sharma M, et al. 2020. Nat Commun. 11:661. PubMed
  66. Mori H, et al. 2015. Toxicol Pathol. 43: 883-889. PubMed
  67. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  68. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  69. Furukawa K,et al. 2017. PLoS One. 10.1371/journal.pone.0184901. PubMed
  70. Zhao F, et al. 2018. Cancer Immunol Res. 1.263194444. PubMed
  71. Gartlan KH, et al. 2019. Blood Adv. 2.110416667. PubMed
  72. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  73. Sharba S, et al. 2019. Virulence. 10:97. PubMed
  74. Xie D, et al. 2020. Eur J Immunol. 50:1729. PubMed
  75. Liu H, et al. 2020. J Immunol. 205:1207. PubMed
  76. Brown IK, et al. 2021. PLoS Pathog. 17:e1009602. PubMed
  77. Zhong X, et al. 2020. Proc Natl Acad Sci U S A. 8563:117. PubMed
  78. Zareie P, et al. 2017. J Neuroinflammation. 0.630555556. PubMed
  79. Kim SJ, et al. 2017. Nat Immunol. 18:1016. PubMed
  80. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  81. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  82. Hsiao CC, et al. 2021. Cells. 10:. PubMed
  83. Dooley K, et al. 2021. Mol Ther. 29:1729. PubMed
  84. Dai Z, et al. 2021. JCI Insight. 6: . PubMed
  85. Sprouse ML, et al. 2018. JCI Insight. 3:e97322. PubMed
  86. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  87. Sheppard S, et al. 2018. Front Immunol. 1.630555556. PubMed
  88. Sharabi A, et al. 2019. JCI Insight. 4:e126294. PubMed
  89. Chihara N, et al. 2018. Nature. 558:454. PubMed
  90. Shin J, et al. 2018. Diabetes. 67:1068. PubMed
  91. Majer O, et al. 2019. Nature. 575:366. PubMed
  92. Tao H, et al. 2021. Front Immunol. 12:623280. PubMed
  93. Jang SC, et al. 2021. Commun Biol. 4:497. PubMed
  94. You X, et al. 2022. Front Genet. 12:790990. PubMed
  95. Zelazowska MA, et al. 2020. Life Sci Alliance. :3. PubMed
  96. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  97. Kenna T, et al. 2008. Blood. 111:2091. PubMed
  98. King IL, et al. 2017. Mucosal Immunol. 10:1160. PubMed
  99. Yates K, et al. 2018. Proc Natl Acad Sci U S A. 115:2162. PubMed
  100. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  101. Oyarce K, et al. 2018. Front Immunol. 9:112. PubMed
  102. Gilfillan CB, et al. 2020. Eur J Immunol. 50:505. PubMed
  103. Chen HW, et al. 2021. Biomedicines. 9:. PubMed
  104. Tan CL, et al. 2018. Immunohorizons. 0.248611111. PubMed
  105. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  106. Yoon BH, et al. 2018. Mol Cells. 41:953. PubMed
  107. Ikezoe T, et al. 2021. Biomolecules. 11:. PubMed
  108. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  109. Dionisio-Santos DA, et al. 2021. Front Neurosci. 15:758677. PubMed
  110. Bajic D, et al. 2020. Mol Cancer Ther. 19:2554. PubMed
  111. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
  112. Kakaradov B, et al. 2017. Nat Immunol. 18:422. PubMed
  113. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  114. Rosenbaum M, et al. 2019. Nat Commun. 2.05. PubMed
  115. Meyers JL, et al. 2018. PLoS One. 13:e0207007. PubMed
  116. Kawabe T, et al. 2017. Sci Immunol. 2:eaam9315. PubMed
  117. Seo SU, et al. 2021. Front Immunol. 12:697162. PubMed
  118. Duncan CG, et al. 2018. G3 (Bethesda). 0.892361111. PubMed
  119. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  120. Ko S, et al. 2005. J Immunol. 175:3309. PubMed
  121. Shissler SC, et al. 2020. Sci Rep. 10:8218. PubMed
  122. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  123. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
  124. Tsai MS, et al. 2021. Int J Mol Sci. 22:. PubMed
  125. Zhang Z, et al. 2020. Front Immunol. 1.844444444. PubMed
  126. Brown ZJ, et al. 2018. Cell Death Dis. 0.805555556. PubMed
  127. Stelekati E, et al. 2018. Cell Rep. 2.445833333. PubMed
  128. Cui X, et al. 2017. J Immunol. 199:4066. PubMed
  129. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
  130. Amobi-McCloud A, et al. 2021. Front Immunol. 12:678999. PubMed
  131. Sami E, et al. 2020. Cancer Res. 80:1102. PubMed
  132. Zhang C, et al. 2018. Cell Res. 28:323. PubMed
  133. Afzali B, et al. 2017. Nat Immunol. 18:813. PubMed
  134. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
  135. Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed
  136. Lee B, et al. 2019. Front Immunol. 0.561805556. PubMed
  137. Dey P, et al. 2020. Cancer Discov. 10:608. PubMed
  138. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  139. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  140. Freed-Pastor WA, et al. 2021. Cancer Cell. 39:1342. PubMed
  141. Fujimura N, et al. 2016. J Vasc Surg. 64: 46-54. PubMed
  142. Englezou PC, et al. 2018. Mol Ther Nucleic Acids. 12:118. PubMed
  143. Cole C, et al. 2018. Nucleic Acids Res. 46:e62. PubMed
  144. Sutherland APR, et al. 2019. Sci Rep. 9:15302. PubMed
  145. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  146. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  147. Pittala S, et al. 2018. Neoplasia. 9:20222. PubMed
  148. Lin J, et al. 2017. Nat Commun. . 10.1038/s41467-017-01477-5. PubMed
  149. Huppé CA, et al. 2018. Mucosal Immunol. 0.536111111. PubMed
  150. Kang JG, et al. 2020. PLoS Negl Trop Dis. 14:e0007813. PubMed
  151. Gorgun FM, et al. 2021. Front Oncol. 11:701968. PubMed
  152. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  153. Lee YJ, et al. 2018. FASEB J. 32:4658. PubMed
  154. Atif SM, et al. 2019. JCI Insight. 4:e125494. PubMed
  155. Khameneh HJ, et al. 2017. J Immunol. 198:196. PubMed
  156. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
  157. Genton C, et al. 2006. J Immunol. 177:2285. PubMed
  158. Jordan J, et al. 2008. Infect Immun. 76:3717. PubMed
  159. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  160. Zhang N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  161. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  162. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  163. Liu H, et al. 2022. Animal Model Exp Med. 5:72. PubMed
  164. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
  165. Fritz Y, et al. 2017. J Invest Dermatol. 137:696. PubMed
  166. Chen YQ, et al. 2019. J Immunother Cancer. 0.415277778. PubMed
  167. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
  168. Kästele V, et al. 2021. Mucosal Immunol. 14:717. PubMed
  169. Prabakaran T, et al. 2021. EBioMedicine. 66:103314. PubMed
  170. Sutiwisesak R, et al. 2020. PLoS Pathog. 16:e1009000. PubMed
RRID
AB_312740 (BioLegend Cat. No. 100701)
AB_312741 (BioLegend Cat. No. 100702)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 5    Revision Date: 12/03/2020

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account